Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

Enhertu (trastuzumab deruxtecan), in combination with pertuzumab, shows promise as a new first-line treatment for ...

In this manuscript, Hua et al. proposed SLC7A11, a protein facilitating cellular cystine uptake, as a potential target for the treatment of trastuzumab resistant HER2 positive breast cancer. If this ...

Brain metastasis is emerging as the most serious concern for breast cancer patients. HER2-positive breast cancer is more prone to undergo brain metastasis than other subtypes; notably, there has been ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

(I) Relations between cysteine metabolic genes and trastuzumab treatment outcomes. Significances were determined by two-tailed unpaired t-test (F, I). ns, P ≥0.05; *, P < 0.05; **, P < 0.01; ***, P < ...

DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 inhibitor. The ...

"This positive CHMP ... face a critical unmet need in HER2-positive biliary tract cancers, a rare and aggressive group of cancers with poor prognosis and limited treatment options," said Robert ...

New research uncovers key factors driving survival and treatment response in patients with HER2-positive breast cancer ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

Aurobindo Pharma's biosimilar for breast cancer recommended for EU approval, demonstrating similarity to Herceptin.